长期暴露于臭氧和慢性阻塞性肺病恶化再入院之间的关联
Huajing Yang1, Zihui Wang2, Yumin Zhou1
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, Postcode, China; Guangzhou National Laboratory, Guangzhou, Guangdong, Postcode, China.
长期暴露于臭氧会显著增加因慢性阻塞性肺病恶化而重新入院的风险. 这种臭氧污染导致了大量的疾病和经济负担,特别是在老年男性身上.
科学领域:
- 环境健康 环境健康
- 肺部病理学 肺部病理学
- 流行病学 流行病学
背景情况:
- 长期暴露于臭氧 (O3) 对慢性阻塞性肺病 (AECOPD) 急性恶化再入院率的影响尚不清楚.
- 慢性阻塞性肺病是住院和再入院的主要原因,造成了大量的医疗保健费用.
- 臭氧是一种主要的空气污染物,具有已知的呼吸系统影响.
研究的目的:
- 调查长期环境臭氧暴露与AECOPD再接收风险之间的关联.
- 为了估计因臭氧暴露而导致的AECOPD再接收的疾病和经济负担.
主要方法:
- 在中国广州 (2014-2015) 收集了个人级别的AECOPD住院数据.
- 年平均臭氧度是根据患者住所地址计算的,该地址是在指数住院治疗之前的.
- 考克斯的比例危险模型被用于评估不同时间点 (30,90,180,365天) 的臭氧暴露与再接收风险之间的关联.
- 采用反事实方法来估计可归因疾病和经济负担.
主要成果:
- 长期臭氧度增加10μg/m3与30天AECOPD再入院风险增加28%有关 (HR 1.28,95%CI 1.09-1.49).
- 对于90日,180日和365日再接收风险也观察到类似的关联.
- 老年患者 (≥75岁) 和男性对臭氧暴露的敏感性增加.
- 臭氧暴露占30天再入院的29.0%,每位参与者可归因的平均成本为362.3美元.
结论:
- 长期暴露于高臭氧度是AECOPD再接收的重要风险因素.
- 臭氧污染对与COPD相关的疾病负担和医疗保健成本做出了重大贡献.
- 针对改善空气质量的公共卫生战略可以减少COPD恶化和相关的医疗保健支出.
更多相关视频
相关概念视频
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation


